Compare MNRO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNRO | ANL |
|---|---|---|
| Founded | 1957 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.6M | 611.1M |
| IPO Year | 1994 | 2022 |
| Metric | MNRO | ANL |
|---|---|---|
| Price | $11.71 | $13.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $16.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 946.9K | 213.3K |
| Earning Date | 05-27-2026 | 04-10-2026 |
| Dividend Yield | ★ 6.69% | N/A |
| EPS Growth | ★ 113.64 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,157,176,000.00 | N/A |
| Revenue This Year | N/A | $36.02 |
| Revenue Next Year | $1.59 | N/A |
| P/E Ratio | $424.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.16 | $0.88 |
| 52 Week High | $23.91 | $17.25 |
| Indicator | MNRO | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 28.55 | 55.67 |
| Support Level | N/A | $12.41 |
| Resistance Level | $18.32 | $13.29 |
| Average True Range (ATR) | 0.83 | 1.08 |
| MACD | -0.38 | 0.04 |
| Stochastic Oscillator | 0.70 | 44.83 |
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.